Format
Sort by
Items per page

Send to

Choose Destination

Links from Gene

Items: 1 to 20 of 459

1.

Upregulation of P21-Activated Kinase 1 (PAK1)/CREB Axis in Squamous Non-Small Cell Lung Carcinoma.

Chung JH, Kim DH, Kim YS, Son BS, Kim D, Hwang C, Shin D, Noh SG, Han JH, Kim DK, Kim JH, Koo JS, Chung HY, Yoon SH.

Cell Physiol Biochem. 2018;50(1):304-316. doi: 10.1159/000494007. Epub 2018 Oct 3.

2.

Effect of PAK1 gene silencing on proliferation and apoptosis in hepatocellular carcinoma cell lines MHCC97-H and HepG2 and cells in xenograft tumor.

Zhang ZL, Liu GC, Peng L, Zhang C, Jia YM, Yang WH, Mao L.

Gene Ther. 2018 Jul;25(4):284-296. doi: 10.1038/s41434-018-0016-9. Epub 2018 May 25.

PMID:
29802374
3.

p21 Activated kinase 1: Nuclear activity and its role during DNA damage repair.

Pérez-Yépez EA, Saldívar-Cerón HI, Villamar-Cruz O, Pérez-Plasencia C, Arias-Romero LE.

DNA Repair (Amst). 2018 May;65:42-46. doi: 10.1016/j.dnarep.2018.03.004. Epub 2018 Mar 21. Review. Erratum in: DNA Repair (Amst). 2018 Aug 23;:.

PMID:
29597073
4.

Cloning and functional characterization of human Pak1 promoter by steroid hormones.

Raghavan S, Venkatraman G, Rayala SK.

Gene. 2018 Mar 10;646:120-128. doi: 10.1016/j.gene.2017.12.039. Epub 2017 Dec 21.

PMID:
29274909
5.

Old drug new tricks: Chlorhexidine acts as a potential allosteric inhibitor toward PAK1.

Huang HW, Zhang XY, Song PL, Jiang HL, Li W, Wang PL, Wang J, Liu FN.

Biochem Biophys Res Commun. 2018 Jan 1;495(1):728-732. doi: 10.1016/j.bbrc.2017.11.087. Epub 2017 Nov 14.

PMID:
29146188
6.

Targeting PAK1.

Semenova G, Chernoff J.

Biochem Soc Trans. 2017 Feb 8;45(1):79-88. doi: 10.1042/BST20160134. Review.

7.

Clinicopathological signature of p21-activated kinase 1 in prostate cancer and its regulation of proliferation and autophagy via the mTOR signaling pathway.

Wang Z, Jia G, Li Y, Liu J, Luo J, Zhang J, Xu G, Chen G.

Oncotarget. 2017 Apr 4;8(14):22563-22580. doi: 10.18632/oncotarget.15124.

8.

P21-activated kinase 1 regulates resistance to BRAF inhibition in human cancer cells.

Babagana M, Johnson S, Slabodkin H, Bshara W, Morrison C, Kandel ES.

Mol Carcinog. 2017 May;56(5):1515-1525. doi: 10.1002/mc.22611. Epub 2017 Feb 23.

9.

Up-regulation of stem cell markers by P21-activated kinase 1 contributes to 5-fluorouracil resistance of colorectal cancer.

Huynh N, Shulkes A, Baldwin G, He H.

Cancer Biol Ther. 2016 Aug 2;17(8):813-23. doi: 10.1080/15384047.2016.1195045. Epub 2016 Jun 3.

10.

Potential role of p21 Activated Kinase 1 (PAK1) in the invasion and motility of oral cancer cells.

Parvathy M, Sreeja S, Kumar R, Pillai MR.

BMC Cancer. 2016 May 16;16 Suppl 1:293. doi: 10.1186/s12885-016-2263-8.

11.

Myricetin suppresses p21-activated kinase 1 in human breast cancer MCF-7 cells through downstream signaling of the β-catenin pathway.

Jiao D, Zhang XD.

Oncol Rep. 2016 Jul;36(1):342-8. doi: 10.3892/or.2016.4777. Epub 2016 Apr 28.

PMID:
27122002
12.

P21-activated kinase 1 (Pak1) signaling influences therapeutic outcome in pancreatic cancer.

Jagadeeshan S, Subramanian A, Tentu S, Beesetti S, Singhal M, Raghavan S, Surabhi RP, Mavuluri J, Bhoopalan H, Biswal J, Pitani RS, Chidambaram S, Sundaram S, Malathi R, Jeyaraman J, Nair AS, Venkatraman G, Rayala SK.

Ann Oncol. 2016 Aug;27(8):1546-56. doi: 10.1093/annonc/mdw184. Epub 2016 Apr 26.

PMID:
27117533
13.

Pak1, adjuvant tamoxifen therapy, and breast cancer recurrence risk in a Danish population-based study.

Ahern TP, Cronin-Fenton DP, Lash TL, Sørensen HT, Ording AG, Hamilton-Dutoit SJ, Hellberg Y.

Acta Oncol. 2016 Jun;55(6):734-41. doi: 10.3109/0284186X.2016.1150606. Epub 2016 Apr 8.

14.

p21-activated kinase 1 (PAK1) expression correlates with prognosis in solid tumors: A systematic review and meta-analysis.

Fang F, Pan J, Li YP, Li G, Xu LX, Su GH, Li ZH, Feng X, Wang J.

Oncotarget. 2016 May 10;7(19):27422-9. doi: 10.18632/oncotarget.8320. Review.

15.

Overexpression of PAK-1 is an independent predictor of disease recurrence in colorectal carcinoma.

Al-Maghrabi J, Emam E, Gomaa W, Al-Qaydy D, Al-Maghrabi B, Buhmeida A, Abuzenadah A, Al-Qahtani M, Al-Ahwal M.

Int J Clin Exp Pathol. 2015 Dec 1;8(12):15895-902. eCollection 2015.

16.

FRAX597, a PAK1 inhibitor, synergistically reduces pancreatic cancer growth when combined with gemcitabine.

Yeo D, He H, Patel O, Lowy AM, Baldwin GS, Nikfarjam M.

BMC Cancer. 2016 Jan 16;16:24. doi: 10.1186/s12885-016-2057-z.

17.

β-elemene enhances the radiosensitivity of gastric cancer cells by inhibiting Pak1 activation.

Liu JS, Che XM, Chang S, Qiu GL, He SC, Fan L, Zhao W, Zhang ZL, Wang SF.

World J Gastroenterol. 2015 Sep 14;21(34):9945-56. doi: 10.3748/wjg.v21.i34.9945.

18.

Potentially functional polymorphisms in PAK1 are associated with risk of lung cancer in a Chinese population.

Zheng M, Liu J, Zhu M, Yin R, Dai J, Sun J, Shen W, Ji Y, Jin G, Ma H, Dong J, Xu L, Hu Z, Shen H.

Cancer Med. 2015 Nov;4(11):1781-7. doi: 10.1002/cam4.524. Epub 2015 Sep 17.

19.

Effects of p21-activated kinase 1 inhibition on 11q13-amplified ovarian cancer cells.

Prudnikova TY, Villamar-Cruz O, Rawat SJ, Cai KQ, Chernoff J.

Oncogene. 2016 Apr 28;35(17):2178-85. doi: 10.1038/onc.2015.278. Epub 2015 Aug 10.

20.

Dysregulation of PAK1 Is Associated with DNA Damage and Is of Prognostic Importance in Primary Esophageal Small Cell Carcinoma.

Gan J, Zhang Y, Ke X, Tan C, Ren H, Dong H, Jiang J, Chen S, Zhuang Y, Zhang H.

Int J Mol Sci. 2015 May 27;16(6):12035-50. doi: 10.3390/ijms160612035.

Supplemental Content

Support Center